Hence, identifying and targeting miRNAs that regulate pathways involved in tumor-associated inflammation and EMT may result in an effective integrative approach to overcome drug resistance in HER2-overexpressing breast cancers. The gene discussed is ERBB2; the disease is breast cancer.